The cost of prescription drugs in the United States has reached a critical point, prompting calls for legislative reform. One proposed solution focuses on limiting the power and influence of pharmacy-benefit managers (PBMs).

PBMs act as intermediaries between drug manufacturers, health insurers, and pharmacies. Their role includes negotiating drug prices and managing formularies. However, critics argue that the current structure of PBM operations contributes to the high prices consumers face. By introducing legislation that alters the regulatory landscape for PBMs, policymakers aim to foster greater transparency and competition within the pharmaceutical supply chain. This approach suggests that adjusting the power dynamics of these key players could lead to more affordable medication prices for American consumers.

Key Takeaways

• U.S. medicine prices are described as "horribly out of control."
• A proposed solution involves enacting laws to limit the power of pharmacy-benefit managers (PBMs).
• Legislation targeting PBMs is seen as a potential mechanism to address rising drug costs.

Further legislative action and regulatory adjustments are anticipated as discussions around drug pricing reform continue.

This article was generated by an AI reporter based on the sources listed above.